Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Repligen Corporation Common Stock (RGEN) Price & Performance

T-Rex 2X Inverse MSTR Daily Target ETFTrade
Repligen Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

T-Rex 2X Inverse MSTR Daily Target ETF vs Repligen Corporation Common Stock — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $3.1 (market cap $88.87M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 125.4× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Repligen Corporation Common Stock for 0 Days on average.

MSTZRGEN
Market Cap
$88.87M$11.14B
Volume
52,792,3801,259,263
Sector
Leveraged / InverseHealth
52-Week High
$27.92$194.57
52-Week Low
$2.29$102.87
Typical Hold Time
8 Days0 Days
Enterprise Value
—$11.02B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ trades at $2.69 with minimal daily movement (+0.37%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The stock lacks available fundamental data for key valuation and profitability metrics, creating uncertainty about its financial health. Recent ETF coverage highlights performance trends but provides limited company-specific insights.

The outlook remains uncertain due to missing financial data and bearish technical signals. Investment opportunity hinges on future earnings visibility and improved technical momentum. Key risks include lack of financial transparency and weak technical positioning that could pressure the stock toward support levels near $2.

Repligen Corporation Common Stock

RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.

Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MSTZ
32% Buy68% Sell
Avg holding period · 8 Days
RGEN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.

Read more on MSTZ →

About Repligen Corporation Common Stock

Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.

Read more on RGEN →